Mice with null mutation of Ceacam1 develop nonalcoholic steatohepatitis
Sumona Ghosh1,2,*, Meenakshi Kaw1,2,*, Payal R Patel1,2, Kelly J Ledford1,2, Thomas A Bowman1,2, Marcia F McInerney1,4, Sandra K Erickson5, Raymond E Bourey1,3, Sonia M Najjar1,2
1Center for Diabetes and Endocrine Research, 2Departments of Physiology and Pharmacology, and of 3Medicine at the University of Toledo College of Medicine, Health Science Campus, Toledo, OH, USA; 4Department of Medicinal and Biological Chemistry at the College of Pharmacy, University of Toledo, Main Campus, Toledo, OH, USA; 5Department of Medicine, University of California, and Veterans Affairs Medical Center, San Francisco, CA, USA; *These authors contributed equally to this work
Abstract: Transgenic liver-specific inactivation of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM1) impairs hepatic insulin clearance and causes hyperinsulinemia, insulin resistance, elevation in hepatic and serum triglyceride levels, and visceral obesity. It also predisposes to nonalchoholic steatohepatitis (NASH) in response to a high-fat diet. To discern whether this phenotype reflects a physiological function of CEACAM1 rather than the effect of the dominant-negative transgene, we investigated whether Ceacam1 (gene encoding CEACAM1 protein) null mice with impaired insulin clearance also develop a NASH-like phenotype on a prolonged high-fat diet. Three-month-old male null and wild-type mice were fed a high-fat diet for 3 months and their NASH phenotype was examined. While high-fat feeding elevated hepatic triglyceride content in both strains of mice, it exacerbated macrosteatosis and caused NASH-characteristic fibrogenic changes and inflammatory responses more intensely in the null mouse. This demonstrates that CEACAM1-dependent insulin clearance pathways are linked with NASH pathogenesis.
Keywords: nonalcoholic steatohepatitis, CEACAM1, high-fat diet, inflammation, apoptosis, fibrosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]